Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis

Pediatrics

Volumn 99, Issue 1, 1997, Pages 93-99

  Connor, Edward ^a  

^a MEDIMMUNE   (United States)

Author keywords

prophylaxis; respiratory syncytial virus; respiratory syncytial virus immune globulin

Indexed keywords

IMMUNOGLOBULIN; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ACROCYANOSIS; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; FEVER; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESTLESSNESS; TREATMENT OUTCOME;

BRONCHOPULMONARY DYSPLASIA; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; LENGTH OF STAY; MALE; PLACEBOS; RESPIRATION, ARTIFICIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 0030959478     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.99.1.93     Document Type: Article

References (22)

1. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone Publishers; 1995:1501-1519
2. Hall CB. Respiratory syncytial virus. What we know now. Contemp Pediatr. November 1993:2-11
3. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med. 1973;288:498-505
4. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol. 1973;98:289-300
5. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986; 140:543-546
6. Institute of Medicine Committee on Issues and Priorities for New Vaccine Development. Prospects for immunizing against respiratory syncytial virus. In: New Vaccine Development, Establishing Priorities. Washington, DC: National Academy of Sciences Press; 1988;1:397-409
7. Groothuis JR, Guiterrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988; 82:199-203
8. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants less than 32 weeks gestation. Pediatrics. 1991;88: 527-532
9. Ogra PL, Patel JP. Respiratory syncytial virus infection and the immunocompromised host. Pediatr Infect Dis J. 1988;7:246-249
10. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med. 1982; 307:397-400
11. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol. 1985;55:517-520
12. Siber GR, Leszczynski J, Pena-Cruz V, et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by a microneutralization assay. J Inject Dis. 1992;165: 456-463
13. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994; 169:1368-1373
14. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524-1530
15. Kobayashi R, Stiehm ER, Burgis GO. Use of intravenous immunoglobulin. In: Eichenwald HE, Ströder J, eds. Pediatric Therapy. 3rd ed. St Louis, MO: Mosby Publishers; 1993:590-599
16. Baker CJ, Melish ME, Hall RT et al. Intravenous immune globulin for prevention of nosocomial infection in low-birth weight neonates. N Engl J Med. 1992;327:213-219
17. Weisman LE, Stoll BJ, Keuser TJ et al. Intravenous immune globulin therapy for early-onset sepsis in premature neonates. J Pediatr. 1992;121: 434-443
18. Fanaroff AA, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med. 1994;330:1107-1113
19. Simoes EAF, Groothuis JR, Tristram DA, et al. Respiratory syncytial virus enriched globulin prevents otitis media in high risk children. J Pediatr. 1996;129:214-219
20. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low income families in relationship to age, sex, ethnic group and maternal antibody level. J Pediatr. 1981;98: 708-715
21. Simoes EAF, Sondheimer HM, Meissner HC, et al. Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial vi-rus in children with congenital heart disease. Pediatr Res. 1996;39(4): 113A. Abstract
22. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost effectiveness analysis. Am J Managed Care. 1996;2: 851-861